Recordati S.p.A. - Recordati licenses a superstatin from Kowa

Press Releases

Recordati licenses a superstatin from Kowa

Milan, 11 October 2001

Recordati announced the signature of an important semi-exclusive licensing agreement with the Japanese company Kowa covering the sale in Italy of pitavastatin, a highly innovative drug for the treatment of hypercholesterolemia which is currently entering clinical phase III on a worldwide basis.

Pitavastatin is a "superstatin" with a remarkable capacity for reducing both the cholesterol fraction associated with high cardiovascular risk (LDL) as well as triglyceride levels, and at the same time increasing the "protective" fraction of cholesterol (HDL). Preliminary clinical data indicate that its high efficacy is associated with an excellent tolerability profile. Pitavastatin promises to become one of the best in its class which is growing rapidly in all industrialized countries.

In Italy, as in the rest of the industrialized world, hypercholesterolemia is quite a common condition and, ever more frequently, guidelines issued by competent authorities recommend adequate treatment in order to reduce morbidity and mortality resulting from cardiovascular events. Statins represent one of the most significant contributions to cardiovascular therapy. Abundant scientific literature supports the clinical benefit which derives from the use of this kind of drugs.

"Pitavastatin is a very innovative product which strengthens our presence in the Italian cardiovascular area creating synergies with Zanedip®, our proprietary antihypertensive and leading drug" declared Giovanni Recordati, Chairman and CEO. "Hypercholesterolemia, hypertension, diabetes and excessive bodyweight are the main cardiovascular risk factors. Recordati will therefore increasingly be a reference point in Italy for the treatment of conditions linked to this type of risk.

Recordati, established in 1926, is a European pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003074447), dedicated to the research, development, manufacturing and marketing of pharmaceuticals and pharmaceutical chemicals, with headquarters in Milan, Italy and operating subsidiaries in France, Portugal, Spain, Switzerland and the United States.

		Home Site Map Alert Service Versione Italiana
About us Pharmaceutical operations Rare diseases Investors Corporate Governance Publications Join Us Contacts
Home Investors Press Releases 2001 Print Page Bookmark Page
Recordati at a glance Key Financial Data Recordati Share Press Releases 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 Company Presentations Annual and Interim Reports Regulated information Shareholders’ Meetings Calendar Analyst Coverage Contacts	Press Releases Recordati licenses a superstatin from Kowa Milan, 11 October 2001 Recordati announced the signature of an important semi-exclusive licensing agreement with the Japanese company Kowa covering the sale in Italy of pitavastatin, a highly innovative drug for the treatment of hypercholesterolemia which is currently entering clinical phase III on a worldwide basis. Pitavastatin is a "superstatin" with a remarkable capacity for reducing both the cholesterol fraction associated with high cardiovascular risk (LDL) as well as triglyceride levels, and at the same time increasing the "protective" fraction of cholesterol (HDL). Preliminary clinical data indicate that its high efficacy is associated with an excellent tolerability profile. Pitavastatin promises to become one of the best in its class which is growing rapidly in all industrialized countries. In Italy, as in the rest of the industrialized world, hypercholesterolemia is quite a common condition and, ever more frequently, guidelines issued by competent authorities recommend adequate treatment in order to reduce morbidity and mortality resulting from cardiovascular events. Statins represent one of the most significant contributions to cardiovascular therapy. Abundant scientific literature supports the clinical benefit which derives from the use of this kind of drugs. "Pitavastatin is a very innovative product which strengthens our presence in the Italian cardiovascular area creating synergies with Zanedip®, our proprietary antihypertensive and leading drug" declared Giovanni Recordati, Chairman and CEO. "Hypercholesterolemia, hypertension, diabetes and excessive bodyweight are the main cardiovascular risk factors. Recordati will therefore increasingly be a reference point in Italy for the treatment of conditions linked to this type of risk. Recordati, established in 1926, is a European pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003074447), dedicated to the research, development, manufacturing and marketing of pharmaceuticals and pharmaceutical chemicals, with headquarters in Milan, Italy and operating subsidiaries in France, Portugal, Spain, Switzerland and the United States.